Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Tax Assets

Deferred tax assets that can reduce taxes payable in future periods.

Viatris Inc.NASDAQ: VTRS

Tax Assets · Q2 FY2026 · quarter ended Jun 2026

Tax assets rises 25.3% from a year ago

Tax assets stood at $1.16B at the end of Q2 FY2026, up 25.3% from a year earlier and up 4.4% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.

Context

  • Tax assets amounted to 3.3% of total assets at the end of Q2 FY2026, up 0.9 pp from a year earlier.
  • Tax assets increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether tax assets keeps rising in the next quarterly balance sheet after a +25.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.16B+4.4% QoQ
Last fiscal yearDec 2025
$1.06B+40.9% YoY
Year agoJun 2025
$924.3M+25.3% since
Tax Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.3%——
1 year+40.9%——
3-year CAGR+4.7%——
5-year CAGR——
10-year CAGR——

Tax Assets history

USD · from the balance sheet

Latest · FY2025
1.06B USD
Year-over-year change
+40.9%
4-year CAGR
-5.5%

Tax Assets vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so tax assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +25.3% is the highest of 7, against a peer median of -8.1%.
  • Tax assets amounts to 3.3% of total assets for VTRS, versus a peer median of 2.7%.
VTRS Competitors
Tax Assets for VTRS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RDYDr. Reddy's Laboratories LimitedSep 2026₹23.26B INR+2.4%+45.1%4.0%
TEVATeva Pharmaceutical Industries LimitedJun 2026$2.16B USD+21.4%+14.5%5.4%
BHCBausch Health Companies Inc.Jun 2026$1.85B USD-8.9%-5.3%7.4%
VTRSViatris Inc.Jun 2026$1.16B USD+25.3%+4.7%3.3%
HLNHaleon plcDec 2025£288.49M GBP—+9.5%0.9%
ALKSAlkermes plcSep 2026$120.77M USD-7.3%+13.9%2.7%
ANIPANI Pharmaceuticals, Inc.Mar 2026$66.56M USD-24.8%-5.3%4.7%
AMPHAmphastar Pharmaceuticals, Inc.Mar 2026$42.46M USD-40.3%+3.3%2.6%
AMRXAmneal Pharmaceuticals, Inc.Jun 2026$0 USD——0.0%
OGNOrganon & Co.Sep 2026$0 USD——0.0%
Peer median (excluding VTRS) —-8.1%+9.5%2.7%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents701.2M1.26B991.9M734.8M1.35B
Short-term Investments233.8M212.6M192.5M355.1M106.4M
Net Receivables4.27B4.14B4.04B3.52B3.35B
Inventory3.98B3.52B3.47B3.85B4B
Other Current Assets1.47B1.31B4.13B913.8M194.8M
Total Current Assets10.9B10.64B12.98B9.52B9.22B
Property, Plant & Equipment (Net)3.48B3.28B3.01B2.92B2.89B
Goodwill12.11B10.43B9.87B9.13B6.75B
Intangible Assets26.13B22.61B19.18B17.07B15.1B
Long-term Investments81.4M1.09B1.14B1.35B815M
Tax Assets1.33B925.9M692.9M753M1.06B
Other Non-current Assets798.5M1.05B821.1M754M1.35B
Total Non-current Assets43.94B39.39B34.71B31.98B27.97B
Total Assets54.84B50.02B47.69B41.5B37.19B
Account Payables1.06B1.16B1.38B1.36B1.29B
Short-term Debt3.35B1.25B1.93B600K2.04B
Tax Payables236.9M279.6M226.8M192.7M0
Deferred Revenue00000
Other Current Liabilities1.41B1.24B1.41B1.34B2.88B
Total Current Liabilities9.88B6.75B7.78B5.78B7.09B
Long-term Debt19.72B18.02B16.19B14.04B12.48B
Deferred Tax Liabilities2.82B2.43B1.74B1.11B892M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.73B1.58B1.35B1.76B1.84B
Total Non-current Liabilities24.47B22.2B19.44B17.09B15.39B
Total Liabilities34.35B28.95B27.22B22.87B22.48B
Common Stock12.1M12.1M12.2M12.3M12.5M
Retained Earnings3.69B5.18B4.64B3.42B(388.3M)
Accumulated OCI(1.74B)(2.76B)(2.75B)(3.21B)(2.71B)
Other Stockholders Equity00000
Minority Interest00000
Total Equity20.49B21.07B20.47B18.64B14.71B
Total Debt23.36B19.53B18.37B14.31B14.7B
Net Debt22.66B18.27B17.38B13.57B13.35B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.